The Global Electronic Drug Delivery Systems Market accounted for over US$ 7.6 billion in 2019. It is anticipated to grow at a CAGR of 8.5% from 2020 to 2030.
The success of the therapy and improvements in the condition of patients are dependent on the formulation of dosage form and the exact delivery of the drug to the desired organ. Electronic Drug Delivery Systems (EDDS) is an important innovation in the field of drug delivery systems as it combines controlled drug release, patient monitoring, and real-time wireless communication. It comprises of medical devices, which are used to infuse drugs, growth hormones, and medicines of the desired quantity in patients. These systems enable patients to administer the therapy and make patients independent of caregivers, drug regimens, and medical professionals, thus reducing the overall healthcare expenditure.
Request Sample Report with Industry Insights of “Biobanking Market” @
Some of the prominent players in the global electronic drug delivery systems market include Merck KGaA, Medtronic, F. Hoffmann-La Roche Ltd, United Therapeutics Corporation, Insulet Corporation., Bayer AG, Novo Nordisk A/S, Amgen Inc., Companion Medical, Tandem Diabetes Care, Inc., and others.
The growth of electronic drug delivery systems can be primarily attributed to factors, such as the increasing number of chronic diseases and a rise in the demand for technologically advanced treatment options. As per the U.S. Department of Health & Human Services, six in ten Americans live with at least one chronic disease – heart disease, cancer, or diabetes. Technological advancements in drug delivery devices have led to the development of electronic drug delivery devices, which provide several advantages over conventional drug delivery devices such as improved efficacy, cost & time effectiveness, autonomous patient-administered therapy, and minimum side effects. This leads to an increased demand for electronic drug delivery systems. Moreover, the development and modernization of healthcare facilities are supporting market growth.
Other factors, such as supportive government policies and improvised reimbursement Mediclaim policies, are expected to provide lucrative growth opportunities for the market. Moreover, investments in R&D by major biopharmaceutical companies for advancements in technologies will also boost market growth.
Segmentation Based On:
- Electronic Injection Pens,
- Electronic Wearable Infusion Pumps,
- Electronic Inhalers,
- Electronic Autoinjectors
- Cardiovascular disease,
- Multiple sclerosis,
- Asthma & COPD
Go For Interesting Discount Here:
Asia Pacific is estimated to be the fast-growing region owing to the increasing prevalence of diabetic patients, COPD, and cardiovascular disorders, along with the rising adoption of technologically advanced treatments in this region. Furthermore, a surge in R&D investments by key market players is further supporting market growth. Additionally, improving healthcare infrastructure and the increasing number of healthcare practitioners in the region will provide a robust growth platform during the forecast period.
Table of Contents
- Market Definition
- Market Classification
- Geographic Scope
- Years Considered for the Study: Historical Years – 2017 & 2018; Base Year – 2019; Forecasted Years – 2020 to 2030
- Currency Used
- RESEARCH METHODOLOGY
- Research Framework
- Data Collection Technique
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Methodology
- Bottom Up Approach
- Top Down Approach
- Data Validation and Triangulation
- Market Forecasting Model
- Limitations/Assumptions of the Study
- ABSTRACT OF THE STUDY
- MARKET DYNAMICS ASSESSMENT
Have any query? Inquiry here for Customization about report at:
About Market Industry Reports:
Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.